Travis Fleming
@tjflemin.bsky.social
Harvard Medical School PhD '25 @bloodgenes.bsky.social lab
Functional genomics, CRISPR screens, Acute Myeloid Leukemia, Drug discovery, targeted protein degradation
@danafarber.bsky.social
@bostonchildrens.bsky.social
@broadinstitute.org
Functional genomics, CRISPR screens, Acute Myeloid Leukemia, Drug discovery, targeted protein degradation
@danafarber.bsky.social
@bostonchildrens.bsky.social
@broadinstitute.org
Reposted by Travis Fleming
Out today in @science.org!
What if you could chart cells' regulatory programs at unprecedented resolution?
In my work with Jorge Martin-Rufino from the @bloodgenes.bsky.social lab, we dissect the genome’s control circuits and find where key genetic variation hides
bit.ly/3YhBMoO
What if you could chart cells' regulatory programs at unprecedented resolution?
In my work with Jorge Martin-Rufino from the @bloodgenes.bsky.social lab, we dissect the genome’s control circuits and find where key genetic variation hides
bit.ly/3YhBMoO
Transcription factor networks disproportionately enrich for heritability of blood cell phenotypes
Most phenotype-associated genetic variants map to noncoding regulatory regions of the human genome, but their mechanisms remain elusive in most cases. We developed a highly efficient strategy, Perturb...
bit.ly
April 3, 2025 at 9:20 PM
Out today in @science.org!
What if you could chart cells' regulatory programs at unprecedented resolution?
In my work with Jorge Martin-Rufino from the @bloodgenes.bsky.social lab, we dissect the genome’s control circuits and find where key genetic variation hides
bit.ly/3YhBMoO
What if you could chart cells' regulatory programs at unprecedented resolution?
In my work with Jorge Martin-Rufino from the @bloodgenes.bsky.social lab, we dissect the genome’s control circuits and find where key genetic variation hides
bit.ly/3YhBMoO
A huge congrats to @dpastoors.bsky.social and @delwelruud.bsky.social for this fantastic work!
Excited to share our preprint on #HemeSky: "MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia"! @delwelruud.bsky.social and co-authors! www.biorxiv.org/content/10.1... [1/15]
MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia
Enhancer translocations, due to 3q26 rearrangements, drive out-of-context MECOM expression in an aggressive subtype of acute myeloid leukemia (AML). Direct depletion of MECOM using an endogenous auxin...
www.biorxiv.org
January 6, 2025 at 5:50 PM
A huge congrats to @dpastoors.bsky.social and @delwelruud.bsky.social for this fantastic work!
Reposted by Travis Fleming
Congrats @tjflemin.bsky.social, @bloodgenes.bsky.social and coauthors! I feel like preprint directly ties together #HemeSky 's favorite two transcription factors: MECOM and CEBPA. As to why these two: I'm heavily biased as our complementary work will also be on biorxiv soon (monday!!)
Stem cell-like states confer poor outcomes in blood cancer—but what mechanisms drive this and how can they be therapeutically targeted? In our new preprint, we show how a single TF represses one enhancer to maintain a subset of high-risk leukemias: 🧵👇
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
January 3, 2025 at 12:51 PM
Congrats @tjflemin.bsky.social, @bloodgenes.bsky.social and coauthors! I feel like preprint directly ties together #HemeSky 's favorite two transcription factors: MECOM and CEBPA. As to why these two: I'm heavily biased as our complementary work will also be on biorxiv soon (monday!!)
Reposted by Travis Fleming
Wonderful to have this work led by @tjflemin.bsky.social along with other colleagues in our laboratory, as well as great collaborators, out on @biorxivpreprint.bsky.social! Stay tuned for exciting complementary work from @dpastoors.bsky.social, Ruud Delwel, and co coming soon!
Stem cell-like states confer poor outcomes in blood cancer—but what mechanisms drive this and how can they be therapeutically targeted? In our new preprint, we show how a single TF represses one enhancer to maintain a subset of high-risk leukemias: 🧵👇
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
January 2, 2025 at 3:40 PM
Wonderful to have this work led by @tjflemin.bsky.social along with other colleagues in our laboratory, as well as great collaborators, out on @biorxivpreprint.bsky.social! Stay tuned for exciting complementary work from @dpastoors.bsky.social, Ruud Delwel, and co coming soon!
Stem cell-like states confer poor outcomes in blood cancer—but what mechanisms drive this and how can they be therapeutically targeted? In our new preprint, we show how a single TF represses one enhancer to maintain a subset of high-risk leukemias: 🧵👇
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
January 2, 2025 at 2:47 PM
Stem cell-like states confer poor outcomes in blood cancer—but what mechanisms drive this and how can they be therapeutically targeted? In our new preprint, we show how a single TF represses one enhancer to maintain a subset of high-risk leukemias: 🧵👇
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Reposted by Travis Fleming
🙏 🙏 Honored to have the work from @tjflemin.bsky.social from our lab featured in the Best of #ASH24!!!
Huge congratulations to both @tjflemin.bsky.social and @bloodgenes.bsky.social! Both Outstanding Abstract Achievement Award and Best of ASH! #ASH24 #ASHKudos @ash-hematology.bsky.social
December 11, 2024 at 12:28 AM
🙏 🙏 Honored to have the work from @tjflemin.bsky.social from our lab featured in the Best of #ASH24!!!
Had a blast presenting our work today at #ASH24! Very grateful for my mentors and colleagues for their support. Stay tuned very soon for more on this study on how we’ve functionally dissected high-risk leukemias
Outstanding presentation at #ASH24 from @tjflemin.bsky.social from our lab, where he discussed his work on the mechanisms by which MECOM drives high-risk AMLs!!! Congratulations, Travis!!!
December 10, 2024 at 6:52 AM
Had a blast presenting our work today at #ASH24! Very grateful for my mentors and colleagues for their support. Stay tuned very soon for more on this study on how we’ve functionally dissected high-risk leukemias
Reposted by Travis Fleming
Please come see @tjflemin.bsky.social present on his groundbreaking work at @ash-hematology.bsky.social #ASH24 that reveals a surprisingly simple regulatory logic for high-risk AMLs ... Happening soon in Manchester Grand Hyatt San Diego Seaport Ballrooms ABCD:
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
Paper: Targeted Protein Degradation Reveals a Repressive Role of Mecom at the <em>CEBPA</Em> Locus to Prevent Differentiation in High-Risk Acute Myeloid Leukemia
ash.confex.com
December 9, 2024 at 11:06 PM
Please come see @tjflemin.bsky.social present on his groundbreaking work at @ash-hematology.bsky.social #ASH24 that reveals a surprisingly simple regulatory logic for high-risk AMLs ... Happening soon in Manchester Grand Hyatt San Diego Seaport Ballrooms ABCD:
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
Reposted by Travis Fleming
#ASH24 Please check out these two abstracts from our laboratory! Travis Fleming will present his talk this afternoon and Alexis Caulier will present his poster this evening!
December 9, 2024 at 6:11 PM
#ASH24 Please check out these two abstracts from our laboratory! Travis Fleming will present his talk this afternoon and Alexis Caulier will present his poster this evening!
Anticipating a hefty hangover from those hot Miami Nights at #ASH24 this weekend? Have no fear! I have the solution. Doctors hate this one trick:
🧵👇
🧵👇
December 5, 2024 at 12:30 AM
Anticipating a hefty hangover from those hot Miami Nights at #ASH24 this weekend? Have no fear! I have the solution. Doctors hate this one trick:
🧵👇
🧵👇